These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 38731819)
1. Di-Iacovo N; Ferracchiato S; Pieroni S; Scopetti D; Castelli M; Piobbico D; Pierucci L; Gargaro M; Chiasserini D; Servillo G; Della-Fazia MA Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731819 [No Abstract] [Full Text] [Related]
2. HOPS and p53: thick as thieves in life and death. Della-Fazia MA; Castelli M; Piobbico D; Pieroni S; Servillo G Cell Cycle; 2020 Nov; 19(22):2996-3003. PubMed ID: 33112208 [TBL] [Abstract][Full Text] [Related]
3. Ferracchiato S; Di-Iacovo N; Scopetti D; Piobbico D; Castelli M; Pieroni S; Gargaro M; Manni G; Brancorsini S; Della-Fazia MA; Servillo G Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281239 [TBL] [Abstract][Full Text] [Related]
4. HOPS/TMUB1 retains p53 in the cytoplasm and sustains p53-dependent mitochondrial apoptosis. Castelli M; Piobbico D; Chiacchiaretta M; Brunacci C; Pieroni S; Bartoli D; Gargaro M; Fallarino F; Puccetti P; Soddu S; Della-Fazia MA; Servillo G EMBO Rep; 2020 Feb; 21(2):e48073. PubMed ID: 31867855 [TBL] [Abstract][Full Text] [Related]
5. HOPS/Tmub1 involvement in the NF-kB-mediated inflammatory response through the modulation of TRAF6. Bellet MM; Pieroni S; Castelli M; Piobbico D; Fallarino F; Romani L; Della-Fazia MA; Servillo G Cell Death Dis; 2020 Oct; 11(10):865. PubMed ID: 33060567 [TBL] [Abstract][Full Text] [Related]
6. Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma. Schilling T; Kairat A; Melino G; Krammer PH; Stremmel W; Oren M; Müller M Biochem Biophys Res Commun; 2010 Apr; 394(3):817-23. PubMed ID: 20233581 [TBL] [Abstract][Full Text] [Related]
7. The Ins and Outs of HOPS/TMUB1 in biology and pathology. Della-Fazia MA; Castelli M; Piobbico D; Pieroni S; Servillo G FEBS J; 2021 May; 288(9):2773-2783. PubMed ID: 32860479 [TBL] [Abstract][Full Text] [Related]
8. A role for c-myc in DNA damage-induced apoptosis in a human TP53-mutant small-cell lung cancer cell line. Supino R; Perego P; Gatti L; Caserini C; Leonetti C; Colantuono M; Zuco V; Carenini N; Zupi G; Zunino F Eur J Cancer; 2001 Nov; 37(17):2247-56. PubMed ID: 11677115 [TBL] [Abstract][Full Text] [Related]
9. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types. Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933 [TBL] [Abstract][Full Text] [Related]
10. Comprehensive Bioinformatic Investigation of TP53 Dysregulation in Diverse Cancer Landscapes. Khan R; Pari B; Puszynski K Genes (Basel); 2024 Apr; 15(5):. PubMed ID: 38790205 [TBL] [Abstract][Full Text] [Related]
11. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877 [TBL] [Abstract][Full Text] [Related]
12. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Song H; Hollstein M; Xu Y Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627 [TBL] [Abstract][Full Text] [Related]
13. Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status. Patyka M; Sharifi Z; Petrecca K; Mansure J; Jean-Claude B; Sabri S Oncotarget; 2016 Sep; 7(37):60245-60269. PubMed ID: 27533246 [TBL] [Abstract][Full Text] [Related]
14. PLA2G16 is a mutant p53/KLF5 transcriptional target and promotes glycolysis of pancreatic cancer. Xia W; Bai H; Deng Y; Yang Y J Cell Mol Med; 2020 Nov; 24(21):12642-12655. PubMed ID: 32985124 [TBL] [Abstract][Full Text] [Related]
15. Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma cells. Nakazawa S; Sakata KI; Liang S; Yoshikawa K; Iizasa H; Tada M; Hamada JI; Kashiwazaki H; Kitagawa Y; Yamazaki Y Biomed Res; 2019; 40(1):37-49. PubMed ID: 30787262 [TBL] [Abstract][Full Text] [Related]
16. A common gain of function of p53 cancer mutants in inducing genetic instability. Liu DP; Song H; Xu Y Oncogene; 2010 Feb; 29(7):949-56. PubMed ID: 19881536 [TBL] [Abstract][Full Text] [Related]
17. p53 in breast cancer subtypes and new insights into response to chemotherapy. Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787 [TBL] [Abstract][Full Text] [Related]
18. TP53 mutations, expression and interaction networks in human cancers. Wang X; Sun Q Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943 [TBL] [Abstract][Full Text] [Related]
19. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin. Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812 [TBL] [Abstract][Full Text] [Related]
20. Transmembrane and ubiquitin-like domain-containing protein 1 (Tmub1/HOPS) facilitates surface expression of GluR2-containing AMPA receptors. Yang H; Takagi H; Konishi Y; Ageta H; Ikegami K; Yao I; Sato S; Hatanaka K; Inokuchi K; Seog DH; Setou M PLoS One; 2008 Jul; 3(7):e2809. PubMed ID: 18665261 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]